MYnd Analytics Awarded Subcontract to Support Suicide Prevention for the U.S. Department of Health and Human Services
MISSION VIEJO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that it has been awarded a subcontract to incorporate its PEER report within a project to develop a suicide prevention toolkit, for the U.S. Department of Health and Human Services (HHS).
George Carpenter, CEO of MYnd stated, “We are honored to be a part of this important project, which involves development of a suicide prevention tool kit for HHS. Importantly, we look forward to leveraging our expertise and the extensive data we have compiled through the PEER registry. By combining artificial intelligence, machine learning and data analytics, we can analyze EEG data to recognize patterns, predict outcomes and personalize medicine, thereby improving patient outcomes and reducing healthcare costs. Multiple studies — including two of our own — have shown a relationship between EEG findings, medication response, and suicidality. We look forward to leveraging this powerful data as part of this new HHS sponsored program.”
About MYnd Analytics
MYnd Analytics, Inc. ( www.myndanalytics.com ) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 40,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
MYnd also operates its wholly owned subsidiarity Arcadian Telepsychiatry Services, LLC which manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as statements regarding market developments, new products and growth strategies, the ability of MYnd’s products to successfully produce objective data and improve efficiency in the treatment of depression and other mental health and psychiatric illnesses, to recognize patterns, predict outcomes and personalize medicine, or improve patient outcomes and reduce healthcare costs, as well as those risks and uncertainties set forth in MYnd’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Crescendo Communications, LLCTel: +1 (212) 671-1020Email: firstname.lastname@example.org